05B · Claim Check

Xanamem · Actinogen XanaMIA · NCT06125951

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Readout
Xanamem · Actinogen XanaMIA · NCT06125951 (opens another website in a new tab)
What the registry or primary source says
Phase 2/3. Primaries: CDR-SB change at 36 weeks; adverse events. N=247; active, not recruiting; primary completion 09.22.2026.
What the headline says
Primary missed: 0.10 points vs placebo, p = 0.65
Verdict
Match

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Claim Check